Results 81 to 90 of about 18,252,794 (250)

Common adverse events associated with the use of ribavirin for severe acute respiratory syndrome in Canada [PDF]

open access: yes, 2003
Although information on efficacy and adverse drug reactions is lacking, ribavirin has been used empirically for the treatment of severe acute respiratory syndrome (SARS). We report common adverse events in 110 patients with suspected or probable SARS who
Dresser, L.   +7 more
core   +1 more source

Safety of three different product doses in autologous chondrocyte implantation: results of a prospective, randomised, controlled trial

open access: yesJournal of Orthopaedic Surgery and Research, 2017
Background This study was conducted to assess the efficacy and safety of the three dose levels of the three-dimensional autologous chondrocyte implantation product chondrosphere® in the treatment of cartilage defects (4–10 cm2) of knee joints.
Christoph Becher   +9 more
doaj   +1 more source

Translating whole‐genome doubling into precision medicine in cancer

open access: yesMolecular Oncology, EarlyView.
Whole‐genome doubling creates a WGD‐positive tumor state characterized by persistent chromosomal instability, karyotypic diversification, and cellular stress. These same biological pressures drive aggressive tumor evolution while exposing therapeutic vulnerabilities, providing a rationale for WGD‐informed precision medicine. Whole‐genome doubling (WGD)
Sejung Lee, Junghyeok Lim, Jinhyuk Bhin
wiley   +1 more source

Summary of the treatment-related adverse events.

open access: yes, 2014
Summary of the treatment-related adverse events.
Oluf Dimitri Røe (109870)   +13 more
core   +1 more source

Adverse Events from Emollient Use in Eczema: A Restricted Review of Published Data

open access: yesDermatology and Therapy, 2019
Atopic dermatitis/eczema is a chronic inflammatory skin condition, and emollients are the first-line treatment. Despite their widespread use, there is uncertainty about the frequency and type of adverse events associated with different emollients.
Alisha Bhanot   +2 more
doaj   +1 more source

PANoptosis in the pathogenesis of myelodysplastic syndromes

open access: yesMolecular Oncology, EarlyView.
PANoptosis, a combination of three types of programmed cell death, is mediated by a large protein complex called a PANoptosome. In healthy bone marrow hematopoietic cells, PANoptosis is restricted by inhibitory signaling. In MDS, bone marrow cells become sensitive to the PANoptotic stimuli due to the aberrant inactivation of inhibitory signaling or ...
Rohit Thalla   +4 more
wiley   +1 more source

Economic burden related to chemotherapy-related adverse events in patients with metastatic breast cancer in an integrated health care system

open access: yes, 2016
Nazia Rashid,1 Han A Koh,2 Hilda C Baca,3 Kathy J Lin,1 Susan E Malecha,4 Anthony Masaquel5 1Drug Information Services, Kaiser Permanente, Downey, 2Southern California Permanente Medical Group, Kaiser Permanente, Bellflower, 3Pharmacy Analytical Services,
Koh HA   +5 more
core  

Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer [PDF]

open access: yes, 2007
Background Selective cyclooxygenase inhibitors may retard the progression of cancer, but they have enhanced thrombotic potential. We report on cardiovascular adverse events in patients receiving rofecoxib to reduce rates of recurrence of colorectal ...
Christopher C. McConkey   +36 more
core   +1 more source

Partial FAK suppression promotes tumor growth, an effect reversed by macrophage p110δ PI3K inactivation

open access: yesMolecular Oncology, EarlyView.
Partial inhibition of focal adhesion kinase (FAK) can paradoxically promote tumor growth, rather than simply producing a weaker antitumor effect than that observed with strong FAK suppression. In breast cancer and melanoma models, targeting p110δ PI3K, particularly in macrophages, counteracted these tumor‐promoting effects, highlighting the importance ...
Lydia Xenou   +4 more
wiley   +1 more source

Cutaneous Adverse Events Related To Treatment With Imatinib

open access: yes, 2014
Treatment with Imatinib is generally well-tolerated, and in the majority of patients side effects are only represented by mild to moderate haematological toxicity (Druker 2001).
SAVOIA, Paola, Fava Paolo
core   +1 more source

Home - About - Disclaimer - Privacy